Strategies targeting FLT3 beyond the kinase inhibitors.

Abstract excerpt

Acute myeloid leukemia (AML) is a hematological malignancy characterized by clonal expansion and differentiation arrest of the myeloid progenitor cells, which leads to the accumulation of immature cells called blasts in the bone marrow and peripheral blood. Mutations in the receptor tyrosine kinase FLT3 occur in 30% of normal karyotype patients with AML and are associated with a higher incidence of relapse and...

Topics

• Humans
• Leukemia, Myeloid, Acute
• Mutation
• Protein Kinase Inhibitors
• Receptor Protein-Tyrosine Kinases
• fms-Like Tyrosine Kinase 3